Cargando…

Targeting depletion of myeloid-derived suppressor cells potentiates PD-L1 blockade efficacy in gastric and colon cancers

Myeloid-derived suppressor cells (MDSCs) have been demonstrated to suppress antitumor immunity and induce resistance to PD-1/PD-L1 blockade immunotherapy in gastric and colon cancer patients. Herein, we found that MDSCs accumulate in mice bearing syngeneic gastric cancer and colon cancer. Death rece...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Yao, Zhou, Cong, Li, Qingli, Cheng, Xiaojiao, Huang, Tinglei, Li, Fuli, He, Lina, Zhang, Baiweng, Tu, Shuiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578486/ https://www.ncbi.nlm.nih.gov/pubmed/36268178 http://dx.doi.org/10.1080/2162402X.2022.2131084

Ejemplares similares

Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors
por: Huang, Tinglei, et al.
Publicado: (2021)

Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer
por: Li, Qingli, et al.
Publicado: (2022)

Utidelone inhibits growth of colorectal cancer cells through ROS/JNK signaling pathway
por: Li, Fuli, et al.
Publicado: (2021)

Bone Marrow-Derived Myofibroblasts Promote Gastric Cancer Metastasis by Activating TGF-β1 and IL-6/STAT3 Signalling Loop
por: Wang, Jianzheng, et al.
Publicado: (2020)

Antibody-activated trans-endothelial delivery of mesoporous organosilica nanomedicine augments tumor extravasation and anti-cancer immunotherapy
por: Huang, Tinglei, et al.
Publicado: (2021)

Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade
por: Grauers Wiktorin, Hanna, et al.
Publicado: (2018)

Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer
por: Srivastava, Minu K., et al.
Publicado: (2012)

3,3′-Diindolylmethane improves antitumor immune responses of PD-1 blockade via inhibiting myeloid-derived suppressor cells
por: Sun, Qi, et al.
Publicado: (2022)

Correction: Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer
por: Srivastava, Minu K., et al.
Publicado: (2012)

Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?
por: Jimbu, Laura, et al.
Publicado: (2021)

Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression
por: Deng, Liufu, et al.
Publicado: (2014)

Early Activation of Myeloid-Derived Suppressor Cells Participate in Sepsis-Induced Immune Suppression via PD-L1/PD-1 Axis
por: Ruan, Wei-Shuyi, et al.
Publicado: (2020)

The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
por: Wang, Jianzheng, et al.
Publicado: (2022)

Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy
por: Li, Xueyan, et al.
Publicado: (2021)

Elimination of acquired resistance to PD-1 blockade via the concurrent depletion of tumour cells and immunosuppressive cells
por: Xue, Gang, et al.
Publicado: (2021)

Effect of Immune Checkpoint Blockade on Myeloid-Derived Suppressor Cell Populations in Patients With Melanoma
por: Sun, Steven H., et al.
Publicado: (2021)

A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer
por: McGray, A. J. R., et al.
Publicado: (2021)

Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade
por: Eissler, Nina, et al.
Publicado: (2016)

Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade
por: Kwong, Tsz Tung, et al.
Publicado: (2020)

Plasma fractalkine contributes to systemic myeloid diversity and PD‐L1/PD‐1 blockade in lung cancer
por: Bocanegra, Ana, et al.
Publicado: (2023)

A PD-1 Inhibitor Induces Complete Response of Advanced Bladder Urothelial Carcinoma: A Case Report
por: Wang, Jianzheng, et al.
Publicado: (2021)

Neutrophils with myeloid derived suppressor function deplete arginine and constrain T cell function in septic shock patients
por: Darcy, Christabelle J, et al.
Publicado: (2014)

Myeloid-derived suppressor cell depletion therapy targets IL-17A-expressing mammary carcinomas
por: Dawod, Bassel, et al.
Publicado: (2020)

Exosomal miRNA-107 induces myeloid-derived suppressor cell expansion in gastric cancer
por: Ren, WeiHong, et al.
Publicado: (2019)

M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer
por: Zhao, Rui, et al.
Publicado: (2020)

HOXC10 Promotes Metastasis in Colorectal Cancer by Recruiting Myeloid-derived Suppressor Cells
por: Yu, Jiao, et al.
Publicado: (2022)

Chrysin targets myeloid‐derived suppressor cells and enhances tumour response to anti‐PD‐1 immunotherapy
por: Li, Yinan, et al.
Publicado: (2022)

An Agent-based Model for Investigating the Effect of Myeloid-Derived Suppressor Cells and its Depletion on Tumor Immune Surveillance
por: Allahverdy, Armin, et al.
Publicado: (2019)

Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion
por: D'Alise, Anna Morena, et al.
Publicado: (2021)

Increased Tuberculosis Incidence Due to Immunotherapy Based on PD-1 and PD-L1 Blockade: A Systematic Review and Meta-Analysis
por: Liu, Kewei, et al.
Publicado: (2022)

Myeloid-derived suppressor cells in transplantation: the dawn of cell therapy
por: Zhang, Weitao, et al.
Publicado: (2018)

Analysis of the Expression and Regulation of PD-1 Protein on the Surface of Myeloid-Derived Suppressor Cells (MDSCs)
por: Nam, Sorim, et al.
Publicado: (2019)

Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy
por: Tomela, Katarzyna, et al.
Publicado: (2023)

Personalized Treatment of Advanced Gastric Cancer Guided by the MiniPDX Model
por: Wang, Jianzheng, et al.
Publicado: (2022)

Therapeutic targeting with DABIL‐4 depletes myeloid suppressor cells in 4T1 triple‐negative breast cancer model
por: Parveen, Sadiya, et al.
Publicado: (2021)

Interactome analysis of myeloid-derived suppressor cells in murine models of colon and breast cancer
por: Aliper, Alexander M., et al.
Publicado: (2014)

PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer
por: Liu, Peng, et al.
Publicado: (2022)

GM-CSF signalling blockade and chemotherapeutic agents act in concert to inhibit the function of myeloid-derived suppressor cells in vitro
por: Gargett, Tessa, et al.
Publicado: (2016)

RIP3 blockade prevents immune-mediated hepatitis through a myeloid-derived suppressor cell dependent mechanism
por: Liu, Man, et al.
Publicado: (2022)

Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells
por: Vito, Alyssa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kenrrp4c6jl7876td89fa71cnp